Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Newer antihyperglycemic drugs have distinctive CV, kidney benefits

Key clinical point: Sodium-glucose contransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have different effects on cardiovascular and kidney disease outcomes in patients with type 2 diabetes.

Major finding: SGLT2 inhibitors significantly reduced hospitalization from heart failure. Reduction in risk of kidney disease progression was driven by microalbuminuria with GLP-1 RAs and by estimated glomerular filtration rate with SGLT2 inhibitors.

Study details: A systematic review and meta-analysis of eight cardiovascular outcomes trials that included 77,242 patients.

Disclosures: Study authors provided disclosures related to AstraZeneca, Amgen, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen Research and Development, and Medimmune, among others.


Zelniker TA et al. Circulation. 2019 Feb 21. doi: 10.1161/CIRCULATIONAHA.118.038868.